Kyntra Bio, Inc. Common Stock —— 图表、价格与新闻 (NASDAQ:KYNB)

展开完整图表

Financials

概览声明统计

每季度年度

Market Capitalization 29.83 M
Employee 34
Founded 1993
CEO N/A
Website www.kyntrabio.com
Headquarter California, United States
FIGI BBG000FW5ZL6
Industry Technology

总收入

净利润

每股基本收益（基本 EPS）

总债务

自由现金流

现金及现金等价物

29.83 M 市值

Kyntra Bio Inc

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.